These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22292772)

  • 1. Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.
    Golubovskaya VM; Ho B; Zheng M; Magis A; Ostrov D; Cance WG
    Anticancer Agents Med Chem; 2013 May; 13(4):546-54. PubMed ID: 22292772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
    Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
    Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
    Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
    Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
    Golubovskaya VM; Figel S; Ho BT; Johnson CP; Yemma M; Huang G; Zheng M; Nyberg C; Magis A; Ostrov DA; Gelman IH; Cance WG
    Carcinogenesis; 2012 May; 33(5):1004-13. PubMed ID: 22402131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
    Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
    Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
    Ucar DA; Kurenova E; Garrett TJ; Cance WG; Nyberg C; Cox A; Massoll N; Ostrov DA; Lawrence N; Sebti SM; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2012 Sep; 11(17):3250-9. PubMed ID: 22894899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of focal adhesion kinase inhibitors in cancer therapy.
    Ma WW
    Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
    Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
    Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
    Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
    Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
    Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
    Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
    Golubovskaya VM; Ho B; Zheng M; Magis A; Ostrov D; Morrison C; Cance WG
    BMC Cancer; 2013 Jul; 13():342. PubMed ID: 23841915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
    Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
    Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational modification of semaxanib and sunitinib for developing a tumor growth inhibitor targeting ATP binding site of tyrosine kinase.
    Kaur J; Kaur B; Singh P
    Bioorg Med Chem Lett; 2018 Jan; 28(2):129-133. PubMed ID: 29208523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.